AM630 – 5 mg

Brand:
Cayman
CAS:
164178-33-0
Storage:
-20
UN-No:
De Minimis - 3077 / 9

AM630 binds selectively to cannabinoid 2 (CB2) over CB1 receptors with Ki values of 31.2 and 5,152 nM, respectively.{13044} AM630 acts as an inverse agonist at CB2 receptors, attenuating the antinociceptive effects of a number of cannabinoids, and as a weak partial agonist at CB1 receptors.{13044,14986,16701} It decreases proliferation and induces arrest of the cell cycle at the G2/M phase in renal cell carcinoma cells.{38338}  

 

Available on backorder

SKU: 10006974 - 5 mg Category:

Description

An inverse agonist at CB2 and partial agonist at CB1 receptors; binds selectively to CB2 over CB1 receptors (Kis = 31.2 and 5,152 nM, respectively); blocks the antinociceptive effects of cannabinoids; decreases proliferation and induces cell cycle arrest in renal cell carcinoma cells


Formal name: [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)-methanone

Synonyms:  6-Iodopravodoline

Molecular weight: 504.4

CAS: 164178-33-0

Purity: ≥98%

Formulation: A crystalline solid


Application|Mass Spectrometry||Product Type|Biochemicals|Receptor Pharmacology|Agonists||Product Type|Biochemicals|Receptor Pharmacology|Inverse Agonists||Research Area|Cancer|Cell Cycle|G2/M||Research Area|Neuroscience|Cannabinoid Research|CB1 & CB2 Receptors||Research Area|Neuroscience|Pain Research